Company Overview

Hyperfine, Inc. (NASDAQ: HYPR) is a U.S.-based medical technology company focused on portable magnetic resonance imaging (MRI) systems and AI-enabled neuroimaging solutions. The company operates in the healthcare technology and medical imaging industries, with a primary emphasis on expanding access to diagnostic imaging in settings where conventional MRI systems are impractical due to cost, infrastructure, or mobility constraints. Hyperfine’s flagship product is the FDA-cleared Swoop Portable MR Imaging System, a low-field portable MRI device designed for bedside neuroimaging in hospitals, intensive care units, emergency departments, and other point-of-care environments.

The company generates revenue primarily through sales and leasing of MRI systems, recurring software and service agreements, and related consumables and support services. Hyperfine’s customer base includes hospitals, academic medical centers, healthcare systems, and research institutions. The company positions itself as a differentiated imaging provider through portability, lower installation requirements, reduced shielding and power demands compared with traditional MRI systems, and integration of artificial intelligence tools intended to improve workflow and image acquisition. Hyperfine was founded in 2014 by Jonathan Rothberg and evolved from a research-driven imaging startup into a publicly traded company following a business combination with a special purpose acquisition company in 2021.

Business Operations

Hyperfine primarily operates through its imaging technology platform centered on the Swoop Portable MR Imaging System and associated software ecosystem. The company’s business model includes direct device sales, subscription-based software offerings, maintenance contracts, training services, and collaborative clinical deployments. Hyperfine’s technology combines low-field MRI hardware, proprietary radiofrequency and magnet designs, cloud-enabled software architecture, and AI-assisted imaging algorithms intended to automate scan workflows and enhance image consistency.

Operations are concentrated in the United States, though the company also markets products internationally through direct commercial activities and distribution relationships. Hyperfine maintains intellectual property related to portable MRI systems and image acquisition technologies. The company has collaborated with hospitals, research institutions, and healthcare organizations to support clinical validation and deployment. Hyperfine has also maintained strategic relationships with technology and healthcare partners to expand adoption of portable neuroimaging solutions in critical care and emergency medicine environments.

Strategic Position & Investments

Hyperfine’s strategic direction centers on expanding the adoption of portable MRI technology, increasing recurring software and service revenue, and broadening clinical use cases for bedside imaging. The company has invested in AI-driven imaging enhancements, workflow automation, remote system management capabilities, and cloud-connected software intended to support scalability across healthcare systems. Its strategy also includes pursuing additional regulatory clearances and clinical evidence generation to support broader physician adoption.

The company has focused investment on product development, commercialization infrastructure, and clinical research rather than large-scale acquisition activity. Hyperfine has emphasized integration of AI technologies into imaging workflows and has participated in collaborations aimed at improving access to neuroimaging in underserved or infrastructure-constrained settings. Public disclosures indicate continued emphasis on expanding the installed base of portable MRI systems and strengthening reimbursement and clinical validation pathways within acute care environments.

Geographic Footprint

Hyperfine is headquartered in Guilford, Connecticut, United States, and its primary operational footprint remains concentrated in North America. The company markets and deploys systems across hospitals and healthcare systems in the United States and has expanded selected commercial activities into international markets through distributors and regional partnerships. Public filings and investor materials indicate activity in parts of Europe, the Middle East, and other international healthcare markets where portable imaging may address infrastructure limitations.

The company’s technology is designed to support deployment flexibility across diverse healthcare environments, including urban hospitals, rural facilities, and mobile care settings. While Hyperfine’s international presence remains smaller relative to major global imaging manufacturers, the company has sought to establish a broader global footprint through regulatory clearances, clinical collaborations, and distributor-supported expansion initiatives.

Leadership & Governance

Hyperfine was founded by Jonathan Rothberg, an entrepreneur and inventor known for work in genomic sequencing and medical technologies. The company operates under a leadership strategy focused on expanding access to diagnostic imaging, advancing portable healthcare technologies, and integrating AI-enabled clinical tools into imaging workflows. Corporate governance and operational oversight are managed through a board structure consistent with publicly listed U.S. healthcare technology companies.

Key executives and leadership personnel include:

• Maria Sainz – President and Chief Executive Officer
• Jonathan Rothberg – Founder and Chairman
• Lise K. G. Bjerre – Chief Financial Officer
• Jeremy B. L. Pomeroy – Chief Technology Officer
• David Castiglioni – Chief Commercial Officer

Information regarding executive roles, operational structure, and strategic priorities has been publicly disclosed through SEC filings, investor presentations, earnings materials, and corporate announcements. Some executive assignments and reporting structures may change over time based on company filings and governance updates.